Back to Search Start Over

Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device

Authors :
Antoni Dziatkowiak
Mirosław Garlicki
Rafał Drwiła
Jerzy Domagała
Karol Wierzbicki
Mirosław Ziętkiewicz
Roman Pfitzner
Source :
The Journal of Thoracic and Cardiovascular Surgery. (2):384-385
Publisher :
American Association for Thoracic Surgery. Published by Mosby, Inc.

Abstract

Bleeding is the most frequent complication related to implantation of a mechanical cardiac assist device. 1 Recombinant activated factor VII (NovoSeven; Novo Nordisk, Bagsvaerd, Denmark) was developed as a prohemostatic agent. We report the successful use of recombinant activated factor VII to control bleeding abnormalities in a patient with a left ventricular assist device (LVAD). Clinical Summary

Details

Language :
English
ISSN :
00225223
Issue :
2
Database :
OpenAIRE
Journal :
The Journal of Thoracic and Cardiovascular Surgery
Accession number :
edsair.doi.dedup.....314218f5e25c75927f9aee367bc08351
Full Text :
https://doi.org/10.1067/mtc.2002.119328